Endomorphin 1 (EM-1) and endomorphin 2 (EM-2) were tested for their capacity to alter immune function. Addition of either of these peptides to murine spleen cells in vitro inhibited antibody formation to sheep red blood cells in a bi-phasic dose dependent manner. Maximal inhibition was achieved at doses in the range of 10 À13 to 10 À15 M. Neither naloxone (general opioid receptor antagonist) nor CTAP (selective mu opioid receptor antagonist) blocked the immunosuppressive effect. To show that there was specificity to the immunosuppressive activity of the peptides, affinity-purified rabbit antibodies were raised against each of the synthetic EM peptides haptenized to KLH and tested for capacity to inhibit immunosuppression. Antibody responses were monitored by a standard solid phase antibody capture ELISA, and antibodies were purified by immunochromatography using the synthetic peptides coupled to a Sepharose 6B resin. Verification of the specificity of affinity-purified antisera was performed by immunodot-blot and solid-phase RIA assays. The antisera specific for both EM-1 and EM-2 neutralized the immunosuppressive effects of their respective peptides in a dose-related manner. Control normal rabbit IgG had no blocking activity on either EM-1 or EM-2. These studies show that the endomorphins are immunomodulatory at ultra-low concentrations, but the data do not support a mechanism involving the mu-opioid receptor.
Introduction
Endomorphin 1 (EM-1) and endomorphin 2 (EM-2) are two C-terminal amidated tetrapeptides, first isolated from bovine brain (Zadina et al., 1997) and then from human brain cortex (Hackler et al., 1997) . Endomorphins (EMs) display the highest selectivity and affinity for the mu-opioid receptor (MOR) in the brain (Zadina et al., 1997) and produce a dose-dependent antinociception after i.c.v (Zadina et al., 1997) or i.t. injection in mice, which is blocked by pretreatment with CTAP, naloxone, and/or funaltrexamine (b-FNA) (Goldberg et al., 1998; Soignier et al., 2000; Huang et al., 2000; Przewlocka et al., 1999; Przewlocki et al., 1999; Stone et al., 1997; Ohsawa et al., 2001) . 
